Development and validation of the PROMIS Pediatric Sleep Disturbance and Sleep-Related Impairment item banks

Forrest, Christopher B.; Meltzer, Lisa J.; Marcus, Carole L.; Motte, Anna de la; Kratchman, Amy; Buysse, Daniel J.; Pilkonis, Paul A.; Becker, Brenda D.; Bevans, Katherine B.

doi:10.1093/sleep/zsy054

Cited by 163 publications

(111 citation statements)

References 49 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…14 The patient-reported outcomes measurement information system (PROMIS) offers well-validated, theoretically based, and rigorously developed assessment tools that measure universally experienced health concepts, and thus are meant to be used across health conditions (www.healthmeasures.net). PROMIS sleep health measures for children (ages 8-17 years) and caregiver-proxy reports (for ages [5][6][7][8][9][10][11][12][13][14][15][16][17] were recently developed and tested for validity against polysomnography in children presenting to a pediatric sleep program, 15 and clinical validity was tested using the 8-item short forms in children with asthma, autism, and eczema. 16 The development process followed PROMIS methodology to establish an item-bank for qualitative assessment, followed by validity testing, and item-response theory analysis.…”

Section: Introductionmentioning

confidence: 99%

Clinical validity of the PROMIS pediatric sleep short forms in children receiving treatment for cancer

Daniel

Groß

Meltzer

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Rates of sleep disturbances vary widely across pediatric cancer studies, partly due to differences in measurement tools. Patient‐reported outcomes measurement information system (PROMIS) offers a rigorously developed, well‐validated pair of pediatric sleep health instruments needed to advance sleep research and clinical practice in pediatric cancer. The current study evaluated the clinical validity of PROMIS pediatric sleep scales (sleep disturbances [SD] and sleep‐related impairment [SRI]) among children in active cancer treatment. Procedure Caregiver‐patient dyads were enrolled during cancer treatment in 2‐12 months after diagnosis: 45 children (ages 8‐17 years) and 102 caregivers of children (ages 5‐17 years) completed PROMIS SD and SRI 8‐item short form self‐report or caregiver‐proxy scales, and caregivers reported the prior week's cancer treatments and blood counts. Results Both scales demonstrated strong internal consistency reliability across reporters. SD and SRI were higher than the PROMIS general population calibration sample for caregivers and patients. Oncology caregivers reported lower SD and SRI than sleep clinic caregivers, but oncology patients were similar to sleep clinic patients. Convergent validity was evidenced through moderate correlations between scales by reporter and both scales being significantly higher in patients taking medications for sleep. There were no significant differences in SD or SRI by diagnostic group, receiving radiation, or having low blood counts. Conclusion The PROMIS SD and SRI short forms are promising measures for pediatric oncology, demonstrating strong internal consistency reliability and multiple indications of clinical validity. Although groups did not differ based on treatment variables, results suggest the need for universal screening for sleep problems during pediatric cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical validity of the PROMIS pediatric sleep short forms in children receiving treatment for cancer

Daniel

Groß

Meltzer

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…in daily activities. 16 The PROMIS scales can also be applied in more participant-friendly formats such as short forms and computerized adaptive tests. Preliminary evidence demonstrating clinical validity of these scales in pediatric oncology is promising.…”

Section: Wake Episodesmentioning

confidence: 99%

“…The National Institutes of Health Patient‐Reported Outcomes Measurement Information System (PROMIS) sleep item banks fulfill many of the abovementioned requirements for assessing overall sleep quality. The PROMIS Sleep Disturbance item bank assesses difficulties with sleep onset, continuity, and quality, and the Sleep‐Related Impairment item bank allows additional investigation into daytime impairments associated with sleep problems, including daytime sleepiness, mood and behavior difficulties, and impact on engagement in daily activities . The PROMIS scales can also be applied in more participant‐friendly formats such as short forms and computerized adaptive tests.…”

Section: Introductionmentioning

confidence: 99%

A call to action for expanded sleep research in pediatric oncology: A position paper on behalf of the International Psycho‐Oncology Society Pediatrics Special Interest Group

et al. 2019

View full text Add to dashboard Cite

Sleep and circadian rhythms are closely related to physical and psychosocial well‐being. However, sleep and circadian rhythm disruptions are often overlooked in children with cancer, as they are frequently considered temporary side effects of therapy that resolve when treatment ends. Yet, evidence from adult oncology suggests a bidirectional relationship wherein cancer and its treatment disrupt sleep and circadian rhythms, which are associated with negative health outcomes such as poor immune functioning and lower survival rates. A growing body of research demonstrates that sleep problems are prevalent among children with cancer and can persist into survivorship. However, medical and psychosocial outcomes of poor sleep and circadian rhythmicity have not been explored in this context. It is essential to increase our understanding because sleep and circadian rhythms are vital components of health and quality of life. In children without cancer, sleep and circadian disturbances respond well to intervention, suggesting that they may also be modifiable in children with cancer. We present this paper as a call to (a) incorporate sleep or circadian rhythm assessment into pediatric cancer clinical trials, (b) address gaps in understanding the bidirectional relationship between sleep or circadian rhythms and health throughout the cancer trajectory, and (c) integrate sleep and circadian science into oncologic treatment.

show abstract

“…Because of the age variation and the heterogeneous nature of sleep complaints, no single questionnaire is adequate for all patients. The Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires on Pediatric Sleep Disturbance and Sleep-Related Impairment may be used to obtain a subjective assessment of daytime sleepiness, impairment in daily function, and difficulties with sleep onset and maintenance [81,82]. The Pittsburgh Sleep Quality Index (PSQI) is a validated and widely used tool to evaluate sleep timing, sleep quality, and sleep efficiency [83].…”

Section: Screening and Diagnostic Approachmentioning

confidence: 99%

Sleep Disorders in Children with Central Nervous System Tumors

Maloney¹,

Lewinter²,

Ward³

et al. 2018

obm neurobiol

View full text Add to dashboard Cite

Sleep complaints are common in pediatric patients with central nervous system (CNS) tumors. These problems may result from disruption of normal homeostatic, circadian, neuroendocrine, and cardiorespiratory pathways and vary by tumor location and treatment received. Children with tumors within the hypothalamus and surrounding regions are prone to excessive daytime sleepiness. Sleep-related breathing disorders, especially those involving abnormal control of breathing, may occur in patients with tumors of the brainstem and posterior fossa. Maintaining a high index of suspicion for sleep disorders in children with CNS tumors is essential for early recognition and treatment. In this article, we will review the various sleep problems reported in pediatric brain tumor survivors, explore underlying neurobiological mechanisms, and discuss approaches to screening and diagnosis.Sleep is an essential physiologic function for growth, cognition, and physical and emotional well-being. It is particularly important in childhood, when the brain and body are undergoing rapid development. Normal sleep occurs through a complex interplay between homeostatic, circadian, neuroendocrine, and cardiorespiratory pathways. Cancer and cancer treatment may cause disruptions and imbalances in these pathways, resulting in abnormal sleep. Compared to the general population, pediatric cancer survivors are more likely to experience sleep problems. Patients with a history of brain tumors are particularly prone to sleep issues. In this article, we will review the physiology of normal sleep, describe the sleep problems and pathophysiologic mechanisms behind disrupted sleep in children with central nervous system (CNS) tumors, and discuss strategies for screening, diagnosis, and management. Sleep Mechanisms and PhysiologySleep and wakefulness. Sleep is fundamentally important in promoting growth, repair, and neurocognitive functioning. The timing, duration, and quality of sleep depend on complex, balanced interactions between sleep-promoting and wake-promoting pathways. The majority of these pathways are housed in the basal forebrain, diencephalon, and brainstem. The balance between sleep and wakefulness is governed by two distinct biologic processes: sleep-wake homeostasis (Process S) and circadian rhythm (Process C) [1]. Homeostatic drive to sleep intensifies with continued wakefulness over time and subsides as an individual sleeps. During the day, the sleep-dependent homeostatic drive is counteracted by sleep-independent circadian arousal mechanisms. Circadian rhythms are coordinated by an internal pacemaker housed in the bilateral suprachiasmatic nuclei (SCN) of the anterior hypothalamus [1]. The near-24 hour circadian rhythm is externally entrained by the light-dark cycle on Earth through direct input received by the SCN from retinal ganglion cells via the retinohypothalamic tract, which runs through the optic chiasm [2,3]. Additional input from the intergeniculate leaflet and median raphe nucleus modulate circadian phase shifts [3]. The SCN sends...

show abstract

Development and validation of the PROMIS Pediatric Sleep Disturbance and Sleep-Related Impairment item banks

Cited by 163 publications

References 49 publications

Clinical validity of the PROMIS pediatric sleep short forms in children receiving treatment for cancer

Clinical validity of the PROMIS pediatric sleep short forms in children receiving treatment for cancer

A call to action for expanded sleep research in pediatric oncology: A position paper on behalf of the International Psycho‐Oncology Society Pediatrics Special Interest Group

Sleep Disorders in Children with Central Nervous System Tumors

Contact Info

Product

Resources

About